New study shows tuberculosis preventive medicine wears off faster in countries with high disease rates

Tuberculosis preventive treatment loses its protective power after just twelve months in places with high disease levels, according to new research published in The Lancet Respiratory Medicine. Medicines given to stop inactive infections from turning active provide strong defense during the first one to two years everywhere. However, the lasting benefits drop off quickly in high-burden nations while remaining effective for eight to thirteen years in areas with low and medium disease rates.

Findings

Researchers analyzed data covering over eighty-four thousand people across twenty-four countries. The team included scientists from Boston University and the University of California, Berkeley. These treatments typically use antibiotics like isoniazid and rifapentine given over a four-month period. Such care supports the World Health Organization goal to end the global epidemic by the year 2035.

Recommendations

Experts suggest that high-burden nations must mix these antibiotic courses with other public health tools. Relying only on preventive drugs is not enough because ongoing community spread reduces their long-term value. A doctoral student in public health at Boston University noted that while the medicines work well initially, rapid declines in heavy disease zones mean leaders need broader strategies.

Context

Tuberculosis remains a major global health challenge, spreading primarily through the air when sick individuals cough or sneeze. Medical systems use preventive care to stop latent infections from becoming active and contagious. Understanding how long these medicines protect people helps health officials plan better defense strategies against the disease.